Shares of Hims & Hers Health climbed 5% on Tuesday following the company's announcement of a new online weight-management service tailored for men in Germany. The move marks a significant step in the telehealth provider's international growth strategy.
The newly launched offering enables patients to undergo private virtual consultations and, where appropriate, receive prescriptions from EU-licensed clinicians. The service also includes ongoing support, and patients requiring in-person care will be directed to local healthcare providers.
Germany represents one of Europe's largest healthcare markets, and this launch underscores Hims' commitment to expanding its presence on the continent. The company acquired London-based digital health platform Zava last year, which provided a foundation for entering markets such as Germany, France, and Ireland.
Addressing unmet demand in Germany
Hims highlighted that its new service targets a significant gap in Germany's weight-management landscape. According to data cited by the company, nearly one in five adults in the country is obese, and over 60% of men are overweight. Access to weight-loss medications is often limited because statutory health insurance typically does not cover these treatments, leaving patients to bear the costs themselves.
The company also referenced survey findings indicating that more than 75% of adults who attempted weight management did so without professional guidance, and 42% preferred not to discuss the topic with their general practitioner. The service aims to bridge this gap by combining online consultations with prescription options and continuous clinical support.
Strategic partnerships and regulatory landscape
Earlier this year, Hims entered into a collaboration with Novo Nordisk to distribute the Danish pharmaceutical company's branded GLP-1 weight-loss medications. This partnership followed a period of legal tensions over compounded alternatives.
Investors are also closely monitoring potential changes in U.S. regulations concerning compounded peptides. The company has prepared for possible regulatory shifts by securing a peptide facility in California and testing ingredients. Hims has expressed interest in products such as sermorelin, glutathione, and NAD+, depending on the final regulatory outcome.
In October, the Department of Health and Human Services advanced an interim policy on certain compounded peptides, which helped lift Hims shares after an advisory committee reviewed several peptides in July and recommended that six of seven, including BPC-157, be allowed for pharmacy compounding. However, these recommendations are not final, and the Food and Drug Administration must still make its decisions and complete the formal rulemaking process. Any expansion into compounded peptide products remains contingent on these regulatory developments.
Challenges and legal scrutiny
Despite its international expansion, Hims faces several headwinds. In late July, the Federal Trade Commission filed a lawsuit alleging deceptive privacy practices involving data sharing with advertising platforms, as well as misleading billing or cancellation practices. These are allegations in the lawsuit.
The company has also encountered margin pressure after shifting from compounded GLP-1 treatments to branded versions earlier this year, even as subscriber growth continued. The financial details of the German launch were not disclosed.
This article is for informational purposes only and does not constitute financial advice.
